千金藥業(600479.SH):婦科千金片、纈沙坦膠囊等13個產品獲得東帝汶藥品註冊登記
格隆匯6月2日丨千金藥業(600479.SH)公佈,公司及控股子公司收到由東帝汶衞生部核准簽發的藥品註冊登記文件,批准公司藥品婦科千金片,子公司湖南千金湘江藥業股份有限公司(簡稱“千金湘江藥業”)的阿奇黴素顆粒、多潘立酮片、氟康唑膠囊、蒙脱石散、纈沙坦膠囊、拉米夫定片、曲匹布通片、鹽酸地芬尼多片、非那雄胺片,子公司湖南千金協力藥業有限公司(簡稱“千金協力藥業”)的苯磺酸氨氯地平片、水飛薊賓葡甲胺片、益肝靈片符合東帝汶藥物標準註冊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.